Welcome to our dedicated page for PSYENCE BIOMEDICAL LTD. SEC filings (Ticker: PBM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Psyence Biomedical Ltd. (PBM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Psyence BioMed files under Form 20-F and furnishes interim and event-driven information on Form 6-K, as reflected in the available filings.
Through these filings, investors can review unaudited interim condensed consolidated financial statements and accompanying Management’s Discussion and Analysis for specified periods, as referenced in a Form 6-K describing financial statements for the three and six months ended September 30 in certain years. Exhibits to Form 6-K reports may also include press releases, equity incentive plan documents, and details of material agreements.
Some PBM filings describe corporate and governance developments, such as changes in executive roles, appointments to the Board of Directors, and amendments to capital arrangements. For example, a Form 6-K outlines the appointment of the company’s Chief Financial Officer to the Board and the entry into an amendment to a Common Stock Purchase Agreement with an investor, providing context on the company’s access to capital.
Other Form 6-K submissions incorporate press releases on topics such as clinical trial progress, strategic investments in PsyLabs, and share-related actions. These filings may be incorporated by reference into the company’s shelf registration statements on Form F-3, as indicated in the text of certain reports.
On Stock Titan, PBM filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can help explain key elements of lengthy filings, highlight changes in capital structure, and clarify the implications of agreements or governance updates. Users can quickly scan for items such as interim financial results, capital management disclosures, and material contracts, and can also monitor how press releases referenced in filings align with the company’s broader clinical and strategic narrative.
Psyence Biomedical Ltd. (PBM) announced the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary created to coordinate its U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development. TIRC is intended to be the dedicated U.S. vehicle for regulated ibogaine development.
Subject to definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, in which Psyence BioMed holds an ownership interest, and will be financed by Psyence BioMed. Jody Aufrichtig will serve as Chief Executive Officer of both Psyence BioMed and TIRC, with Dr. John Thorne as project lead. The company highlights that ibogaine remains a controlled substance and is not approved for therapeutic use, and it outlines regulatory, financing and policy risks that could affect the planned activities.
Psyence Biomedical Ltd. (PBM) has filed a Form F-3 to register for resale up to 1,148,598 Common Shares previously issued in private placements. All shares are being offered by existing holders Psyence Labs Ltd. and Outside The Box Capital Inc.; PBM is not selling any shares and will not receive resale proceeds.
PBM will bear registration and listing expenses, while selling holders cover their own selling costs. The company, an emerging growth company and foreign private issuer, develops nature-derived psilocybin and ibogaine-based therapeutics and holds a significant equity stake in Psyence Labs, its psychedelic API partner.
Psyence Biomedical Ltd. presents an August 2026 investor update describing its clinical-stage focus on nature-derived psychedelic therapeutics for mental health in cancer palliative care, Alcohol Use Disorder, Substance Use Disorder and longevity science. The company highlights having no debt, a strong cash position and two low-cost financing mechanisms, and a vertically integrated platform via a strategic equity stake and supply partnership with PsyLabs for GMP-compliant psilocybin, ibogaine, DMT and mescaline.
The presentation details an Australian Phase IIb trial of NPX-5, a botanical psilocybin, for Adjustment Disorder associated with cancer in the palliative care setting, with 87 patients across three dose arms and a HAM-A primary endpoint at ten weeks, following HREC ethics approval, first patient dosing and FDA Pre-IND feedback. Psyence BioMed outlines an anticipated pathway with topline results planned in H1 2027 and future regulatory interactions, and emphasizes intellectual property efforts and potential data exclusivity. It also describes its ibogaine program, notes a $23.3B projected global palliative care market by 2032 and references a recent U.S. executive order committing $50 million to ibogaine research, framing a supportive external environment for its pipeline.
Psyence Biomedical Ltd. files its annual Form 20-F as a clinical-stage biotechnology company focused on psilocybin-based therapies. The report emphasizes that the company has never generated revenue and recorded net profit/(loss) of ($6.89 million), $1 million and ($50.96 million) for the years ended March 31, 2026, 2025 and 2024, respectively.
Psyence discloses it is financing operations through equity and convertible debt, expects significant losses for the foreseeable future, and will require substantial additional funding to advance its Phase IIb study in Australia and potential Phase III program. As of March 31, 2026, cash, cash equivalents and restricted cash totaled USD$7,491,954, which management expects will fund operations beyond 12 months from the filing date.
The company outlines extensive risks, including clinical, regulatory and supply-chain uncertainty, dependence on key partners and licensed IP, U.S. Schedule I status for psilocybin and ibogaine, intense competition in psychedelic therapies, evolving governmental policy, and the possibility that future research, regulation or public perception could materially harm demand for its prospective products.
PSYENCE BIOMEDICAL LTD. amendment reports that Jeffrey David Weiner beneficially owns 59,750 common shares, equal to 2.61% of the class. The filing states this percentage is based on 2,293,307 total outstanding shares reported by the company. The form is signed on 06/09/2026 and is labeled as an amendment to prior ownership disclosure.
Psyence Biomedical Ltd. filed a Form 6-K as a foreign private issuer to report a technical change to its 2023 Equity Incentive Plan. On May 4, 2026, the board approved an amendment and restatement of the plan to correct a typographical error in Section 4(b).
The updated plan, referred to as the First Amended and Restated Equity Incentive Plan, is provided in full as Exhibit 10.1. The filing does not describe any change to plan substance beyond this correction and is signed by the company’s Chief Financial Officer, Warwick Corden-Lloyd.
Psyence Labs Ltd. has filed a Schedule 13D reporting a new major ownership position in Psyence Biomedical Ltd.. Psyence Labs acquired 1,146,159 Common Shares in a share-for-share exchange valued at US$5,000,000, giving it beneficial ownership of about 30.05% of Psyence Biomedical’s outstanding Common Shares.
The Issuer issued these shares in exchange for 2,900 ordinary shares of Psyence Labs, with no cash paid by either party. Psyence Labs describes the holdings as an investment and may, depending on market and company conditions, buy more securities, sell some or all of its stake, or engage in hedging or similar transactions.
Psyence BioMed has begun dosing patients in a Phase IIb clinical trial of NPX-5, a 25mg nature-derived psilocybin candidate, for Adjustment Disorder in cancer patients in a palliative care setting across clinical sites in Australia.
The randomized, double-blind, three-arm study is designed to evaluate both the safety and therapeutic potential of NPX-5 within a structured, therapy-supported treatment model. This is the first active clinical evaluation of NPX-5 and marks a shift toward systematic human data generation within the company’s Australian clinical network.
The program is positioned as a core element of Psyence BioMed’s vertically integrated platform, which combines GMP-compliant manufacturing, clinical development, and global supply capabilities, with the aim of addressing significant unmet mental health needs using nature-derived psychedelic-based therapeutics.
Psyence Biomedical Ltd. updated its common stock purchase agreement with White Lion Capital to add a new intraday share sale option. During the commitment period, Psyence can issue an Intraday Purchase Notice requiring White Lion to buy common shares up to 5% of the Average Daily Trading Volume per notice.
The purchase price is the lowest traded price during a one-hour valuation window after White Lion’s written acceptance, subject to a floor price set in each notice. White Lion must consent within 15 minutes and settle within two business days. In connection with the amendment, White Lion will pay Psyence a $22,000 legal document preparation fee.